2 not yet recruiting, 2 recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Obrixtamig: new trials by email Literature Review of Obrixtamig trials Research Report on Obrixtamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-28 | 2026-10-27 |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 55 | 2026-10-01 | 2026-10-13 |
| A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung Obrixtamig - Large Cell Neuroendocrine Carcinoma of the Lung | Phase 2 | Not yet recruiting | Technische Universität Dresden | 75 | 2026-09-01 | 2026-08-26 |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay - Small Cell Lung Carcinoma, Neuroendocrine Neoplasms | Phase 2 | Recruiting | Boehringer Ingelheim | 204 | 2023-10-13 | 2026-07-23 |
Small Cell Lung Carcinoma (3) · Carcinoma, Neuroendocrine (1) · Lung Neoplasms (1)
Boehringer Ingelheim (3) · Technische Universität Dresden (1)
Belgium (3) · China (3) · France (3) · Germany (3) · Japan (3) · Spain (3) · United States (3) · Australia (2) · Netherlands (2) · Poland (2) · United Kingdom (2) · Bulgaria (1) · Portugal (1) · South Korea (1) · Taiwan (1)
Martin Wermke, Prof. Dr. med. (1)
2023 (1), 2025 (1)